Wilson W R, Whitmore G F, Hill R P
Cancer Res. 1981 Jul;41(7):2817-22.
The cytotoxic activity of 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), a novel acridine derivative with clinical antitumor activity, has been examined in multicellular spheroids grown from Chinese hamster V79-171b cells. m-AMSA is much less effective against cells within these tumor-like structures than it is against exponential-phase V79-171b cells in monolayer cultures, the initial D0 of the survival curve for the latter being approximately 10-fold lower than for the former following a 60-min exposure to the drug. The resistance of spheroid cells to m-AMSA appears to be at least partially a result of the noncycling or slowly cycling state of the majority of these cells, although they are more sensitive than cells in plateau-phase monolayers. A further component of resistance in spheroids requires the presence of an intact spheroid structure and may be due to drug transport limitations. The use of sequential trypsinization techniques to recover cells at varying depths within spheroids demonstrates that a 60-min m-AMSA treatment preferentially kills cells nearest the spheroid surface, suggesting that tumor cells at a distance from the vasculature may limit the efficacy of m-AMSA in vivo.
4'-(9-吖啶基氨基)甲磺基间茴香胺(m-AMSA)是一种具有临床抗肿瘤活性的新型吖啶衍生物,其细胞毒性活性已在中国仓鼠V79-171b细胞生长的多细胞球体中进行了检测。与单层培养中的指数期V79-171b细胞相比,m-AMSA对这些肿瘤样结构内的细胞的作用效果要差得多,在接触该药物60分钟后,后者存活曲线的初始D0比前者低约10倍。球体细胞对m-AMSA的抗性似乎至少部分是由于这些细胞中的大多数处于非循环或缓慢循环状态,尽管它们比处于平台期单层的细胞更敏感。球体抗性的另一个因素需要完整的球体结构存在,并且可能是由于药物转运限制。使用顺序胰蛋白酶消化技术回收球体不同深度的细胞表明,60分钟的m-AMSA处理优先杀死最靠近球体表面的细胞,这表明远离脉管系统的肿瘤细胞可能会限制m-AMSA在体内的疗效。